Ovarian cancer is the leading cause of death from gynecological malignancies in the USA with an overall five-year survival rate of 50%. The NIH panel on ovarian cancer concluded that """"""""innovative approaches to the treatment of advanced primary as well as recurrent ovarian cancer must be identified and studied"""""""". This conclusion supports the research proposed in this application. The purpose of this project is to draw on the advances made in molecular biology, polymer science, chemotherapy, and photodynamic therapy to develop a novel therapeutic modality, which will be potentially more effective than existing therapeutic agents in ovarian cancer treatment. Clinical data indicate that the therapeutic use of nanosized (5-20 nm) water- soluble polymer-anticancer drug conjugates appears to be a novel and successful strategy for cancer treatment. The advantages of polymer-bound drugs (when compared to low-molecular weight drugs) are: a) active uptake by fluid-phase pinocytosis (non-targeted polymer-bound drug) or receptor-mediated endocytosis (targeted polymer-bound drug);b) increased active accumulation of the drug at the tumor site by targeting;c) increased passive accumulation of the drug at the tumor site by the enhanced permeability and retention effect;d) long-lasting circulation in the bloodstream;e) decreased non-specific toxicity of the conjugated drug;f) decreased immunogenicity of the targeting moiety;f) immuno-protecting and immunomobilizing activities;and g) and modulation of the cell signaling and apoptotic pathways. The main aim of the proposed research is to design new, effective macromolecular therapeutics for the treatment of cancer. Macromolecular therapeutics based on conjugates of N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers with Biologic Response Modifiers, 4-hydroxyphenyl retinamide and all- trans-retinoic acid, and conjugates with anticancer drugs, geldanamycin, 2,5-bis(6-hydroxymethyl-2- thienyl)furan, and mesochlorin e6 will be designed and synthesized. A novel therapeutic modality will be developed: pretreatment of cancer cells with macromolecular retinoids will lead to differentiation of cancer cells resulting in enhanced susceptibility to chemotherapy and/or photodynamic therapy. The pretreatment will be followed by administration of a polymer-bound chemotherautic agent and a polymer-bound photosensitizer. Combinatorial chemistry approaches will be used to identify human ovarian carcinoma CD47 binding peptides. A secondary library will be constructed based on results of alanine scanning. This will permit to select peptides with high binding affinity. Multivalent peptide-targeted conjugates will be designed and evaluated. Mechanism of action of macromolecular therapeutics will be studied in detail. The results will provide a basis for the design of double-targeted conjugates - to the receptor expressed at the plasma membrane and to a subcellular location identified for each particular drug by mechanistic studies. The concept of double-targeted macromolecular therapeutics provides a new paradigm for the design of efficient anticancer drugs for the treatment of ovarian cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Prasanna, Pat G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Utah
Schools of Pharmacy
Salt Lake City
United States
Zip Code
Yang, Jiyuan; Kope?ek, Jind?ich (2016) Design of smart HPMA copolymer-based nanomedicines. J Control Release 240:9-23
Yang, Jiyuan; Kope?ek, Jind?ich (2015) POLYMERIC BIOMATERIALS AND NANOMEDICINES. J Drug Deliv Sci Technol 30:318-330
Duangjai, Acharaporn; Luo, Kui; Zhou, Yan et al. (2014) Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells. Eur J Pharm Biopharm 87:187-96
Yang, Jiyuan; Kope?ek, Jind?ich (2014) Macromolecular therapeutics. J Control Release 190:288-303
Kope?ek, Jind?ich (2013) Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev 65:49-59
Zhou, Yan; Kope?ek, Jind?ich (2013) Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target 21:1-26
Pan, Huaizhong; Sima, Monika; Yang, Jiyuan et al. (2013) Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy. Macromol Biosci 13:155-60
Fowers, Kirk D; Kope?ek, Jind?ich (2012) Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates. Macromol Biosci 12:502-14
Pan, Huaizhong; Yang, Jiyuan; Kopeckova, Pavla et al. (2011) Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules 12:247-52
Yang, Jiyuan; Luo, Kui; Pan, Huaizhong et al. (2011) Synthesis of Biodegradable Multiblock Copolymers by Click Coupling of RAFT-Generated HeterotelechelicPolyHPMA Conjugates. React Funct Polym 71:294-302

Showing the most recent 10 out of 82 publications